Eye Care Network Staff

Glaukos finishes US pivotal enrollment for PRESERFLO MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with reassuring safety.

Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, faster workflow.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

The multicenter study is evaluating ZOC2017217, a lanosterol-derived investigational eye drop, ahead of a planned phase 3 trial.

The randomized, double-masked, 3-arm trial did not achieve its primary endpoint of replicating the visual function improvements observed in a smaller phase 1/2a study.

The non-exclusive license agreement pairs Alcon's PCIOL optical designs with RxSight's post-operative light-adjustable platform, with the aim of allowing surgeons to fine-tune visual outcomes after cataract surgery.

Antineoplastics were the most frequently implicated drug class in review

Cascade Prodrug and Uneedle are partnering to test suprachoroidal delivery of CPD100 using Uneedle's Bella-Vue microneedle system for the treatment of wet AMD.